EUVIMEDEUVIMED entdecken
Crossref

Differences in Severity of Poison Centers Exposures Involving XTAMPZA ® ER Versus Other Opioid Analgesics

Stevan Geoffrey Severtson, Emily E Haanschoten, Janetta Iwanicki, Richard C Dart

Pain Management · 2023

DOI: 10.2217/pmt-2022-0068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Management, 2023. Verfasst von Stevan Geoffrey Severtson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO 80204, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Opioid-Related Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Collegium Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims: Xtampza® ER (Collegium Pharmaceutical, MA, USA) is an abuse-deterrent formulation (ADF) of oxycodone intended to deter tampering for use by unintended routes of administration. We assessed whether Xtampza ER exposures were less likely to result in severe medical outcomes relative to other opioid analgesic exposures. Materials & methods: Exposures reported to participating poison centers between 2016 and 2021 inclusive that were followed to a known medical outcome were analyzed. Xtampza ER was compared with other ADF opioids, non-ADF extended-release opioids, single-entity oxycodone immediate-release, unspecified oxycodone and unspecified morphine. Results & conclusion: No Xtampza ER exposures involved unintended routes of administration. Xtampza ER exposures were less likely to be abuse, misuse or suspected suicidal, and medical outcomes were less severe than comparators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidOpioid-Related DisordersHumansOxycodoneDelayed-Action PreparationsMorphine

Stichwörter der Autor:innen

abuseabuse-deterrent formulationsmisuseopioidsroutes of administration

Substanzen

Analgesics, OpioidOxycodoneDelayed-Action PreparationsMorphine

Autor:innen und Institutionen

  • Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO 80204, USA.

Förderung

  • Collegium Pharmaceutical

Zitieren

APA

Severtson, S. G., Haanschoten, E. E., Iwanicki, J., & Dart, R. C. (2023). Differences in Severity of Poison Centers Exposures Involving XTAMPZA ® ER Versus Other Opioid Analgesics. Pain Management. https://doi.org/10.2217/pmt-2022-0068

Vancouver

Severtson SG, Haanschoten EE, Iwanicki J, Dart RC. Differences in Severity of Poison Centers Exposures Involving XTAMPZA ® ER Versus Other Opioid Analgesics. Pain Management. 2023. doi:10.2217/pmt-2022-0068

BibTeX
@article{Severtson2023,
  author = {Severtson, Stevan Geoffrey and Haanschoten, Emily E and Iwanicki, Janetta and Dart, Richard C},
  title = {Differences in Severity of Poison Centers Exposures Involving XTAMPZA ® ER Versus Other Opioid Analgesics},
  journal = {Pain Management},
  year = {2023},
  doi = {10.2217/pmt-2022-0068}
}
Kostenlos starten →